RxDoctor Payments Data

Ketan Patel, MD

Internal Medicine · Carrollton, TXNPI 1003814146

Payments from drug & device makers

$11,079in general payments, 2019–2025

Across 69 payments — averaging $160.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Biodelivery Sciences International, Inc.$7K
  • Boehringer Ingelheim International GmbH$2K
  • Pulmonx Corporation$810
  • Kerecis Limited$330
  • Smith+Nephew$272
  • Organogenesis Inc.$235
  • plus $707 from 10 others

What the payments were for

  • Speaking & faculty fees$5,98067%
  • Travel & lodging$1,01111%
  • Food & beverage$1,95322%

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,079 in reported general payments places this provider in the 90th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$569,201
Medicare patients
670
Services billed
6,546

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban505$165,333
IngrezzaValbenazine Tosylate17$61,699
JardianceEmpagliflozin123$32,100
JanuviaSitagliptin Phosphate100$26,260
XareltoRivaroxaban77$20,283
Atorvastatin Calcium1,164$15,125
TradjentaLinagliptin71$14,514
NeuproRotigotine16$14,166
Gabapentin888$13,347
Memantine Hcl397$12,939
Potassium Chloride474$11,817
EntrestoSacubitril/Valsartan33$11,249
ZenpepLipase/Protease/Amylase37$9,076
RexultiBrexpiprazole15$8,691
Divalproex Sodium390$8,525

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$40$11,24933 claims
Smith+NephewSantyl$272$5,43514 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in Carrollton

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →